Epithalon vs Elamipretide
Compare the research, key figures and safety notes.
How they differ
Both get sold under a longevity banner but stand on very different evidence. Epithalon is a tiny four-piece peptide whose human data traces back to a single research group. Elamipretide (SS-31) targets the cell's energy factories (mitochondria), was run through a proper trial, and became a licensed US medicine in 2025 at 40 mg a day. Both clear within a few hours.
Side by side
| Measure | Epithalon | Elamipretide |
|---|---|---|
| Category | Longevity | Longevity |
| Evidence | D · From community reports | A · Human dose research |
| Route | Route not established | Subcutaneous |
| Half-life | 0.5 h | 2 h |
| Typical vial | 10 / 20 mg | 40 mg |
| Research amount | 5–10 mg | 40–40 mg |
| Common schedule | Every day | Every day |
| Cycle / break | — | — |
| Studied for | Aging and longevity | Aging and longevity |
These amounts and schedules are figures discussed in research and community reports, shared for learning — not a recommendation and not medical advice. A step-by-step dosing schedule exists only where a human trial backs it; the evidence tier tells you which.
Decay curves, overlaid
Each line is scaled to that compound's own first dose, so the chart shows how each one builds up over time — not how the compounds' doses compare to one another, which these different molecules share no common unit for.